First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...
Abbott, a global healthcare leader, announced it has received CE Mark and Health Canada approval for its Amplatzer Steerable Delivery Sheath, which is used with the company's market-leading Amplatzer ...
Abbott is recalling the steerable sheath used to deliver its Amplatzer Amulet Left Atrial Appendage Occluder, saying there is an increased risk of air emboli being introduced to patients undergoing ...
First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...
Abbott Laboratories (NYSE:ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased risk for air bubbles (air emboli) to be introduced into patients who have procedures with this ...
Abbott has received a new, broad approval from the FDA for its tiny heart plug implant to help cut down the risk of stroke among people with atrial fibrillation, the most common cardiac arrhythmia.
Photo Credit: Hermiller J. AMULET: device characteristics, procedural technique, clinical outcomes, and ongoing studies. Presented at: TCT 2019. The US Food and Drug Administration has approved the ...
Abbott has launched its Amplatzer Tailsman PFO Occlosion System in Europe. The device is designed to treat people with a patent foramen ovale (PFO) who have had a stroke and are at risk of having ...
Abbott Laboratories received FDA approval for its Amplatzer Amulet left atrial appendage occluder to treat people with atrial fibrillation who are at risk of ischemic stroke about a month earlier than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results